Migraine, psychiatric comorbidities, and treatment

Headache

Volumn 48, Issue 6, 2008, Pages 952-958

  Evans, Randolph W ^a   Rosen, Noah ^a  

^a NONE

Author keywords

Anxiety; Bipolar disorder; Comorbidity; Depression; Migraine

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; CITALOPRAM; DESIPRAMINE; DOXEPIN; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PHENELZINE; PLACEBO; PROPRANOLOL; RISPERIDONE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT; PAROXETINE; TRYPTAMINE DERIVATIVE;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENCY; DRUG WITHDRAWAL; HAIR LOSS; HUMAN; HYPERSOMNIA; HYPOMANIA; HYPOTENSION; LETHARGY; LIVER DISEASE; MALIGNANT HYPERTENSION; MANIA; MENTAL CONCENTRATION; MENTAL DISEASE; METABOLIC SYNDROME X; MIGRAINE; MOOD DISORDER; MOTOR DYSFUNCTION; NOTE; ORTHOSTATIC HYPERTENSION; PATIENT SATISFACTION; PREVALENCE; PRIORITY JOURNAL; RASH; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADULT; ARTICLE; CASE REPORT; FEMALE; GENETICS; HOSPITALIZATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; FEMALE; HUMANS; MIGRAINE DISORDERS; PAROXETINE; SEVERITY OF ILLNESS INDEX; TRYPTAMINES;

EID: 44849097816     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01074.x     Document Type: Note

References (54)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
2. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache. 2006 46 : 1327 1333.
3. Baskin SB, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache. 2006 46 (Suppl. 3 S76 S87.
4. Sheftell FD. Understanding the headache patient with complex comorbidities: A headache specialist's perspective. Headache. 2006 46 (Suppl. 3 S165 S167.
5. Lipchik GL, Penzian DB. Psychiatric comorbidities in patients with headaches. Semin Pain Med. 2004 2 : 93 105.
6. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: An epidemiologic study of young adults. Psychiatry Res. 1991 37 : 11 23.
7. Patel NV, Bigal ME, Kolodner KB, et al. Prevalence and impact of migraine and probable migraine in a health plan. Neurology. 2004 63 : 1432 1438.
8. Breslau N, Lipton RB, Stewart WF, et al. Comorbidity of migraine and depression: Investigating potential etiology and prognosis. Neurology. 2003 60 : 1308 1312.
9. Zwart JA, Dyb G, Hagen K, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trondelag Health Study. Eur J Neurol. 2003 10 : 147 152.
10. Breslau N. Psychiatric comorbidity in migraine. Cephalalgia. 1998 18 (Suppl 22 56 61.
11. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: An epidemiologic study of young adults. Psychiatry Res. 1991 37 : 11 23.
12. Swartz KL, Pratt LA, Armenian HK, Lee LC, Eaton WW. Mental disorders and the incidence of migraine headaches in a community sample: Results from the Baltimore Epidemiologic Catchment area follow-up study. Arch Gen Psychiatry. 2000 57 : 945 950.
13. Baskin SB, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache. 2006 46 (Suppl. 3 S76 S87.
14. Merikangas KR, Stevens DE. Comorbidity of migraine and psychiatric disorders. Neurol Clin. 1997 15 : 115 123.
15. Merikangas KR, Merikangas JR, Angst J. Headache syndromes and psychiatric disorders: Association and familial transmission. J Psychiatr Res. 1993 27 : 197 210.
16. Radat F, Swendsen J. Psychiatric comorbidity in migraine: A review. Cephalalgia. 2004 25 : 165 178.
17. Verri AP, Proietti Cecchini A, Galli C, Granella F, Sandrini G, Nappi G. Psychiatri comorbidity in chronic daily headache. Cephalalgia. 1998 18 (Suppl 21 45 49.
18. Guidetti V, Galli F, Fabrizi P, et al. Headache and psychiatric comorbidity: Clinical aspects and outcome in a 8-year follow-up study. Cephalalgia. 1998 18 : 455 462.
19. Lake A III., Lipchik D, Penzian D, Rains J, Saper J, Lipton R. Psychiatric comorbidity with chronic daily headache: Evidence based clinical implications - introduction to the supplement. Headache. 2006 46 (Suppl. 3 S73 S75.
20. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache. 2006 46 : 1327 1333.
21. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001 41 : 638 645.
22. Huffman JC, Stern TA. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci. 2007 9 : 29 45.
23. Shapiro RE, Tepper SJ. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache. 2007 47 : 266 269.
24. Hendrix Y, van Zagten MS. Serotonin syndrome as a result of concomitant use of paroxetine and sumatriptan Ned Tijdschr Geneeskd. 2005 149 : 888 890.
25. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996 16 : 323 327.
26. Evans R. FDA Alert on serotonin syndrome with combined use of SSRI's and SNRI's and triptans: An analysis of the 29 case reports. Med Gen Med. 2007 9 : 48.
27. O'Bryant SE, Marcus DA, Rains JC, Penzien DB. The neuropsychology of recurrent headache. Headache. 2006 46 : 1364 1376.
28. Nash JR, Thebarge RW. Understanding psychological stress, its biological processes, and impact on primary headache. Headache. 2006 46 : 1377 1386.
29. Couch JR, Hassanein RS. Amitryptiline in migraine prophylaxis. Arch Neurol. 1979 36 : 695 699.
30. Gomersall JD, Stuart A. Amitryptiline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry. 1973 36 : 684 690.
31. Amelin AV, Skoromets AA, Korenko LA, BCh T, Gonchar MA. A comparative efficiency of amitryptiline, fluoxetine and maprotiline in prevention of migraine in attack-free period. Zh Nevrol Psikhiatr Im S S Korsakova. 2000 100 : 20 23.
32. Griffith JL, Razavi M. Pharmacological management of mood and anxiety disorders in headache patients. Headache. 2006 46 (Suppl 3 S133 S141.
33. Walker Z, Walker RW, Robertson MM, Stansfeld S. Antidepressant treatment of chronic tension-type headache: A comparison between fluoxetine and desipramine. Headache. 1998 38 : 523 528.
34. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskom SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitryptyline. Arch Neurol. 1987 44 : 486 489.
35. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitryptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: A double-blind study. Headache. 2002 42 : 510 514.
36. Pringsheim T, Diksic M, Dobson C, Nguyen K, Hamel E. Selective decrease in serotonin synthesis rate in rat brainstem raphe nuclei following chronic administration of low doses of amitryptiline: An effect compatible with an anti-migraine effect. Cephalalgia. 2003 23 : 367 375.
37. Bank J. A comparative study of amitryptiline and fluvoxamine in migraine prophylaxis. Headache. 1994 34 : 476 478.
38. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache. 1992 32 : 101 104.
39. D'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: A double-blind trial. Headache. 1999 39 : 716 719.
40. Saper JR, Silberstein SD, Lake AE III., Winters ME. Double-blind trial of fluoxetine: Chronic daily headache and migraine. Headache. 1994 34 : 497 502.
41. Bendtsen L, Jensen R, Olesen J. A non-selective (amitryptiline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 61 : 285 290.
42. Martucci N, Manna V, Agnoli A. Antidepressant drugs and migraine. Cephalalgia. 1985 5 (Suppl. 2 225 228.
43. Kathpal GS. Role of SSRI's in the management of migraine. Headache Q Curr Treat Res. 1998 9 : 265 266.
44. Briley M. Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Hum Psychoparmacol. 1998 13 : 99 111.
45. Diamond S. Efficacy and safety profile of venlafaxine in chronic headache. Headache Q Curr Treat Res. 1995 6 : 212 214.
46. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000 40 : 572 580. 992. 101 104.
47. Nascimento ED. Prophylaxis of migraine: Open study with venlafaxine in 42 patients. Arq Neuropsiquiatr. 1998 56 : 744 746.
48. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitryptiline in the prophylactic treatment of migraine: Randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004 107 : 44 48.
49. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005 45 : 144 152.
50. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep. 2003 7 : 51 54.
51. Levy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol. 2003 18 : 301 303.
52. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: A double blind study versus placebo. Cephalalgia. 1992 12 : 81 84.
53. Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005 76 : 1730 1732.
54. Silberstein SD, Peres MF, Hopkins M, Schecter AL, Young W, Rozen T. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002 42 : 515 518.